In this article , which was published in the March 2011 issue of Cancer Prevention Research (1), there was an erroneous entry for 2 data-points at the 4 g dose due to author error. Figure 2 in the article had 1 endpoint errantly deleted from the figure but not from statistical calculations. The means in Fig. 2 change slightly at the 4 g dose. The P value remains unchanged and the Aberrant Crypt Foci (ACF) change at the 2 g dose remains insignificant while still significant at the 4 g dose (P < 0.005). The corrected figure appears below.
Human rectum with ACF number at initial exam and 30 days post treatment with 2 gm or 4 gm of curcumin. For each dose group, horizontal lines indicate the mean value for pre- and post-treatment levels in each dose group, with the standard error of the mean indicated by the endpoints of the corresponding vertical lines. Pre- and post-treatment levels of ACF number are plotted for each individual patient. The paired t-test was applied to examine change from pre-treatment levels in ACF number at a significance level 0.05.
Human rectum with ACF number at initial exam and 30 days post treatment with 2 gm or 4 gm of curcumin. For each dose group, horizontal lines indicate the mean value for pre- and post-treatment levels in each dose group, with the standard error of the mean indicated by the endpoints of the corresponding vertical lines. Pre- and post-treatment levels of ACF number are plotted for each individual patient. The paired t-test was applied to examine change from pre-treatment levels in ACF number at a significance level 0.05.
RSS Feeds